136 0 Kommentare IsoRay's Proprietary Cesium-131 Product Line Will Be on Display at the American Society for Radiation Oncology (ASTRO) Convention

RICHLAND, WA--(Marketwired - October 14, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth (505) at the 57^thAnnual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place October 18-21, 2015 in San Antonio, Texas at the Henry B. Gonzalez Convention Center. According to IsoRay CEO Dwight Babcock, "The medical community is becoming increasingly aware of the innovative alternatives that our products offer as an important advance over previous brain, lung, prostate and gynecologic cancer treatments."

IsoRay's Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite^®radiation therapy system give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after tumor removal or when placed directly within the organ. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, providing important benefits for patients in longevity as well as quality of life.

Babcock says "These private dinners provide a forum for peer to peer discussions with other leaders who share their successes in the use of Cesium-131 for some of their most challenging cases. Medical thought leaders recognize the important need for this new powerful weapon in the battle against cancer and Cesium-131 is that solution. A number of new institutions are in the process of licensing Cesium-131 for use within their facility."

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices including the GliaSite® radiation therapy system.